Previous 10 | Next 10 |
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , April 13, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Ja...
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded today at $131.83, eclipsing its 52-week high. Approximately 89.8 million shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares. Based on a current price of $85.13, BioMarin Pharmaceutical...
Alnylam specializes in commercialized and in-pipeline RNA interference (RNAi) therapeutics. Sarepta’s commercial portfolio focuses on Duchenne muscular dystrophy (DMD), a genetic disorder of progressive muscular weakness, typically in young boys. BioMarin is a commercial st...
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded today at $131.83, eclipsing its 52-week high. So far today approximately 89.8 million shares have been exchanged, as compared to an average 30-day volume of 1.4 million shares. BioMarin's focus is on rare-disease therapies. Genz...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...
Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A PR Newswire New England Journal of Medicine Publishes Editorial: Prepare ...
FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...
BioMarin released positive financials, but investors were disappointed by some clinical trial data. Voxzogo: positive start to sales, but negative data from trials in children under five years old. ValRox: waiting for the EU approval. For further details see: BioMarin: K...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...